Lung Cancer in China: A Treatment Pathway Guide
How diagnosis, staging and treatment decisions are typically organised for international patients, and what to prepare before travelling.
Understanding the diagnostic pathway
Most international lung-cancer patients arrive with imaging from their home country — usually a CT scan that found a nodule or mass. Chinese thoracic centres will typically repeat or extend the imaging locally, because treatment planning depends on images taken to a consistent protocol. Expect a contrast-enhanced CT of the chest and upper abdomen, and in many cases a PET-CT, before any tissue is discussed.
Tissue confirmation is the next step for most patients. A bronchoscopy with biopsy, or a CT-guided needle biopsy for peripheral lesions, is arranged based on where the nodule sits. Molecular testing on the biopsy sample — looking for EGFR, ALK, ROS1 and other driver alterations — is standard practice in major Chinese cancer centres, and the results shape whether targeted therapy is an option alongside surgery or chemoradiotherapy.
What staging means for your options
Staging describes how far the cancer has spread, and it is the single biggest factor in treatment planning. Early-stage disease (stage I and II) is generally considered for surgery, often with minimally invasive techniques. Locally advanced disease (stage III) usually involves a combination of chemotherapy and radiotherapy, sometimes with surgery after a response. Stage IV disease is treated predominantly with systemic therapy — targeted drugs, immunotherapy or chemotherapy, chosen according on the molecular profile.
Your coordinator should ask the hospital to provide the staging work-up as a written report. This matters twice: once for you to understand the plan, and once for your physician at home, who will take over follow-up care after you return.
Surgery, radiotherapy and systemic therapy
If surgery is recommended, you will meet a thoracic surgeon to discuss the approach — open thoracotomy versus video-assisted (VATS) or robotic techniques — and what lung function testing is needed beforehand. Hospital stays after minimally invasive lung surgery are commonly five to seven days, with a chest drain for part of that time.
Radiotherapy is delivered in daily sessions over one to seven weeks depending on the technique. Stereotactic body radiotherapy (SBRT) for early-stage disease, or definitive chemoradiation for locally advanced disease, both require you to stay near the hospital for the full course. Systemic therapy runs on two- to four-week cycles; many international patients arrange the first cycles in China and continue maintenance treatment at home with a shared medication plan.
Preparing your medical records
Bring digital copies of everything: prior imaging in DICOM format (not just the written reports), pathology slides or blocks if a biopsy was already done, recent blood work, and a full list of medications with doses. Records in English are workable at all major centres; translation is rarely a blocker, but a glossary of your own medical history helps the team move faster.
If you are already on treatment — targeted therapy, immunotherapy or chemotherapy — carry the medication itself in original packaging with a prescription letter, and confirm customs rules for the quantity you bring in.
Practical timeline and costs to expect
A realistic first trip runs two to three weeks: several days for repeated imaging and biopsies, three to seven days for pathology and molecular results, then consultations to set the plan. If treatment starts in China, budget for a longer stay or a planned second trip.
Costs vary with the pathway. A diagnostic work-up at a Grade 3A hospital commonly falls in the USD 3,000–8,000 range; surgery is typically quoted in advance as a package after the pre-operative assessment. Ask your coordinator for a written estimate before agreeing to a plan, and keep every invoice — many international insurers require itemised originals for reimbursement.